Smith & Nephew Announces Key ADS Purchase by Executive

Smith & Nephew Snats ( (SNN) ) has issued an announcement.

On November 6, 2025, Smith & Nephew plc announced a significant transaction involving the purchase of American Depositary Shares (ADS) by Ajay Dhankhar, the Chief Corporate Strategy & Development Officer, on the New York Stock Exchange. This transaction, disclosed under the UK Market Abuse Regulation, highlights the company’s ongoing strategic activities and could indicate confidence in the company’s future performance, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (SNN) stock is a Hold with a $36.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.

Spark’s Take on SNN Stock

According to Spark, TipRanks’ AI Analyst, SNN is a Neutral.

Smith & Nephew Snats’ strong financial performance and positive earnings call are the main drivers of its stock score. However, bearish technical indicators and a high P/E ratio temper the overall outlook. The company’s strategic initiatives, such as the share buyback, reflect confidence in its financial health, but challenges in emerging markets and tariff impacts pose risks.

To see Spark’s full report on SNN stock, click here.

More about Smith & Nephew Snats

Smith & Nephew plc is a global medical technology company that specializes in the development and manufacturing of advanced medical devices, including orthopedics, sports medicine, and wound management products. The company is focused on providing innovative solutions to improve patient outcomes and is a key player in the healthcare industry.

Average Trading Volume: 667,925

Technical Sentiment Signal: Buy

Current Market Cap: $15.51B

Find detailed analytics on SNN stock on TipRanks’ Stock Analysis page.